Literature DB >> 23212286

Panitumumab rechallenge in chemorefractory patients with metastatic colorectal cancer.

Akito Hata1, Nobuyuki Katakami, Shiro Fujita, Kento Takatori, Aya Horai, Naoto Kitajima, Kazuki Terashima.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23212286     DOI： 10.1007/s12029-012-9453-7

Source DB:  PubMed          Journal:  J Gastrointest Cancer


× No keyword cloud information.
  15 in total

1.  Rechallenge with oxaliplatin and fluoropyrimidine for metastatic colorectal carcinoma after prior therapy.

Authors:  Amanda R Townsend; Sarwan Bishnoi; Vy Broadbridge; Carol Beeke; Christos S Karapetis; Kunal Jain; Colin Luke; Robert Padbury; Timothy J Price
Journal:  Am J Clin Oncol       Date:  2013-02       Impact factor: 2.339

2.  Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients.

Authors:  Daniele Santini; Bruno Vincenzi; Annalisa La Cesa; Marco Caricato; Gaia Schiavon; Bruno Spalletta; Marisa Di Seri; Roberto Coppola; Laura Rocci; Giuseppe Tonini
Journal:  Oncology       Date:  2005-07-28       Impact factor: 2.935

3.  Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection.

Authors:  Akito Hata; Nobuyuki Katakami; Hiroshige Yoshioka; Shiro Fujita; Kei Kunimasa; Shigeki Nanjo; Kyoko Otsuka; Reiko Kaji; Keisuke Tomii; Masahiro Iwasaku; Akihiro Nishiyama; Hidetoshi Hayashi; Satoshi Morita; Tadashi Ishida
Journal:  Lung Cancer       Date:  2011-05-06       Impact factor: 5.705

4.  Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Authors:  Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

5.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

6.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

7.  Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report.

Authors:  James Heun; Kyle Holen
Journal:  Clin Colorectal Cancer       Date:  2007-05       Impact factor: 4.481

8.  Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.

Authors:  Carsten Bokemeyer; Igor Bondarenko; Anatoly Makhson; Joerg T Hartmann; Jorge Aparicio; Filippo de Braud; Serban Donea; Heinz Ludwig; Gunter Schuch; Christopher Stroh; Anja H Loos; Angela Zubel; Piotr Koralewski
Journal:  J Clin Oncol       Date:  2008-12-29       Impact factor: 44.544

9.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321

10.  Safety and efficacy of panitumumab following cetuximab: retrospective review of the Memorial Sloan-Kettering experience.

Authors:  Derek G Power; Manish A Shah; Timothy R Asmis; Joaquin J Garcia; Nancy E Kemeny
Journal:  Invest New Drugs       Date:  2009-05-26       Impact factor: 3.850
View more
  5 in total

1.  Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

Authors:  Giulia Siravegna; Benedetta Mussolin; Michela Buscarino; Giorgio Corti; Andrea Cassingena; Giovanni Crisafulli; Agostino Ponzetti; Chiara Cremolini; Alessio Amatu; Calogero Lauricella; Simona Lamba; Sebastijan Hobor; Antonio Avallone; Emanuele Valtorta; Giuseppe Rospo; Enzo Medico; Valentina Motta; Carlotta Antoniotti; Fabiana Tatangelo; Beatriz Bellosillo; Silvio Veronese; Alfredo Budillon; Clara Montagut; Patrizia Racca; Silvia Marsoni; Alfredo Falcone; Ryan B Corcoran; Federica Di Nicolantonio; Fotios Loupakis; Salvatore Siena; Andrea Sartore-Bianchi; Alberto Bardelli
Journal:  Nat Med       Date:  2015-06-01       Impact factor: 53.440

2.  Successful cetuximab therapy after failure of panitumumab rechallenge in a patient with metastatic colorectal cancer: restoration of drug sensitivity after anti-EGFR monoclonal antibody-free interval.

Authors:  Akito Hata; Nobuyuki Katakami; Naoto Kitajima
Journal:  J Gastrointest Cancer       Date:  2014-12

Review 3.  Integrating liquid biopsies into the management of cancer.

Authors:  Giulia Siravegna; Silvia Marsoni; Salvatore Siena; Alberto Bardelli
Journal:  Nat Rev Clin Oncol       Date:  2017-03-02       Impact factor: 66.675

Review 4.  Heterogeneity of Colorectal Cancer Progression: Molecular Gas and Brakes.

Authors:  Federica Gaiani; Federica Marchesi; Francesca Negri; Luana Greco; Alberto Malesci; Gian Luigi de'Angelis; Luigi Laghi
Journal:  Int J Mol Sci       Date:  2021-05-15       Impact factor: 5.923

Review 5.  Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer.

Authors:  Richard M Goldberg; Clara Montagut; Zev A Wainberg; Philippe Ronga; François Audhuy; Julien Taieb; Sebastian Stintzing; Salvatore Siena; Daniele Santini
Journal:  ESMO Open       Date:  2018-05-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.